Diagnostics

Upstream Bio verekitug met NPS target in 79% of VIBRANT patients

Post-hoc responder analyses from the Phase 2 VIBRANT trial show verekitug achieved clinically meaningful nasal polyp improvements in roughly four in five treated
Post-hoc responder analyses from the Phase 2 VIBRANT trial show verekitug achieved clinically meaningful nasal polyp improvements in roughly four in five treated
The Biotech Times Editorial Team  · 
Diagnostics

Vivoryon touts DKD kidney data as it hunts Phase 2b partner

The Dutch biotech reported compelling eGFR data in diabetic kidney disease patients and confirmed cash runway only into Q4 2026 as partnership talks continue.
The Dutch biotech reported compelling eGFR data in diabetic kidney disease patients and confirmed cash runway only into Q4 2026 as partnership talks continue.
The Biotech Times Editorial Team  · 
Biotech

Zymeworks ZW191 posts 78.6% response rate in FRα-positive ovarian cancer

Phase 1 data for the ADC showed activity across both FRα-positive and FRα-negative platinum-resistant ovarian cancer patients at ESMO Gynaecological Cancers 2026.
Phase 1 data for the ADC showed activity across both FRα-positive and FRα-negative platinum-resistant ovarian cancer patients at ESMO Gynaecological Cancers 2026.
The Biotech Times Editorial Team  · 
Genomics

AC Immune gets $4m Goradia grant to extend Parkinson's vaccine trial

The philanthropic grant extends Part 1 of the Phase 2 VacSYn trial of ACI-7104 by two years, with final Part 1 data due in
The philanthropic grant extends Part 1 of the Phase 2 VacSYn trial of ACI-7104 by two years, with final Part 1 data due in
The Biotech Times Editorial Team  · 
Genomics

Agios RISE UP Phase 3 data show mitapivat cuts transfusion burden in SCD

New analyses from Agios's EHA 2026 plenary presentation show mitapivat reduced transfusion burden by 41% and improved pain and fatigue in sickle cell responders.
New analyses from Agios's EHA 2026 plenary presentation show mitapivat reduced transfusion burden by 41% and improved pain and fatigue in sickle cell responders.
The Biotech Times Editorial Team  · 
Synthetic Biology

Genmab epcoritamab shows high response rates in elderly DLBCL patients

Phase 2 data presented at EHA 2026 show epcoritamab monotherapy and a combination regimen achieved strong complete response rates in first-line elderly DLBCL patients.
Phase 2 data presented at EHA 2026 show epcoritamab monotherapy and a combination regimen achieved strong complete response rates in first-line elderly DLBCL patients.
The Biotech Times Editorial Team  · 
Diagnostics
Genomics

IMDX GraftAssure CM-Score lifts kidney rejection PPV to 81%

Insight Molecular Diagnostics says its combination model score outperforms single-metric dd-cfDNA in a peer-reviewed study of 414 kidney transplant patients.
Insight Molecular Diagnostics says its combination model score outperforms single-metric dd-cfDNA in a peer-reviewed study of 414 kidney transplant patients.
The Biotech Times Editorial Team  · 

Intellia Phase 3 HAELO data show 87% HAE attack reduction

Phase 3 results for lonvo-z, published simultaneously in the NEJM, showed 62% of patients attack-free over six months with a single dose.
Phase 3 results for lonvo-z, published simultaneously in the NEJM, showed 62% of patients attack-free over six months with a single dose.
The Biotech Times Editorial Team  · 
Regulatory Science

MBX Biosciences: one-year canvuparatide data in hypoparathyroidism

One-year open-label extension data show a 57% responder rate for canvuparatide, with Phase 3 on track to start in Q3 2026.
One-year open-label extension data show a 57% responder rate for canvuparatide, with Phase 3 on track to start in Q3 2026.
The Biotech Times Editorial Team  · 
Bioprocessing

Neion Bio closes $23m Series A for egg-based biologics platform

The New York biotech raised an oversubscribed Series A led by Caffeinated Capital to scale its Raptor egg-based biomanufacturing platform.
The New York biotech raised an oversubscribed Series A led by Caffeinated Capital to scale its Raptor egg-based biomanufacturing platform.
The Biotech Times Editorial Team  · 
Pharmaceuticals

J&J talquetamab plus daratumumab cuts RRMM death risk by up to 53%

Phase 3 MonumenTAL-3 data show talquetamab combinations beat standard care on PFS and OS in earlier-line relapsed myeloma.
Phase 3 MonumenTAL-3 data show talquetamab combinations beat standard care on PFS and OS in earlier-line relapsed myeloma.
The Biotech Times Editorial Team  · 
Regulatory Science

Ascendis Pharma TransCon PTH sustains efficacy at 3.5 years in Phase 3

Week 182 PaTHway Trial data show palopegteriparatide maintained biochemical normalisation and quality-of-life gains across multi-organ systems in adults with
Week 182 PaTHway Trial data show palopegteriparatide maintained biochemical normalisation and quality-of-life gains across multi-organ systems in adults with
The Biotech Times Editorial Team  · 
Subscribe to